Mutations in Ras or other oncogenic drivers are rare in PM, which is mostly characterised by loss in tumour suppressors such as BAP1, p16 and p53 [39], but several groups including ours have previously demonstrated strong MAPK activation via fibroblast growth factor receptor (FGFR) signalling in PM [16, 40]. This evidence concerns the gene TP53 and neoplasm.